Detalhe da pesquisa
1.
Genomic imbalances analysis provides new insight into prognostic factors in adult and pediatric T-ALL.
Blood
; 2024 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38518104
2.
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.
Blood
; 140(7): 756-768, 2022 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35443031
3.
Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: A nationwide CEREO study.
Am J Hematol
; 99(6): 1108-1118, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38563187
4.
Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.
Blood
; 138(7): 507-519, 2021 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34410352
5.
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
Blood
; 137(20): 2827-2837, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33881523
6.
A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia.
Blood
; 137(4): 524-532, 2021 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32871585
7.
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Blood
; 138(26): 2753-2767, 2021 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34724563
8.
Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r.
BMC Bioinformatics
; 23(1): 448, 2022 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36307762
9.
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Br J Haematol
; 198(3): 535-544, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35438802
10.
Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study).
Rheumatology (Oxford)
; 61(11): 4355-4363, 2022 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35176141
11.
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.
Blood
; 135(8): 542-546, 2020 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31880804
12.
A 17-gene stemness score for rapid determination of risk in acute leukaemia.
Nature
; 540(7633): 433-437, 2016 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27926740
13.
Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias.
Genes Chromosomes Cancer
; 60(10): 657-667, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33982372
14.
Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use.
Haematologica
; 106(6): 1767-1769, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33299234
15.
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape
Haematologica
; 106(12): 3056-3066, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054115
16.
Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.
Blood
; 131(3): 289-300, 2018 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29051182
17.
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia.
Blood
; 132(2): 187-196, 2018 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29692343
18.
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Blood
; 131(12): 1275-1291, 2018 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29330221
19.
Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients.
Am J Hematol
; 95(11): 1314-1323, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32720700
20.
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.
Int J Mol Sci
; 21(16)2020 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32781546